Blu Biotech Inc. Announces Patent Licensing Agreement with University of Michigan


ALBUQUERQUE, New Mexico, November 2, 2022 /PRNewswire/ — Blu Biotech Inc. has entered into a patent license agreement with Innovation Partnerships in University of Michigan (UM) to develop and commercialize a Gas Chromatography Photoionization Detector (Micro-GC-PID), which uses a patient’s breath to diagnose various forms of cancer, COVID-19 and associated variants, distress syndrome acute respiratory tract disease (ARDS), sepsis, and other acute and chronic inflammatory diseases. This new diagnostic test device was developed at the College of Engineering and the Weil Institute for Critical Care Research and Innovation through the efforts of Dr. Xudong Fan from the Department of Biomedical Engineering and Dr. Kevin Ward from the UM Department of Emergency Medicine.

Blu Biotech Inc. Announces Patent License Agreement with University of Michigan for cancer breath test technology

Under the terms of the agreement, Blu Biotech will produce and market the device for use in diagnostic testing. Blu Biotech has the right to exclusively use the technology for breath analysis products in United States and Canada, Europe, and not exclusively in other parts of the world. The commercial device will combine high-performance breath analysis with point-of-care use for the diagnosis and monitoring of multiple diseases. Last month, two of the principal investigators conducting clinical trials on behalf of Blu Biotech presented groundbreaking results for lung cancer detection and colorectal detection at the International Thoracic Surgical Oncology Summit in New York and the 17th Scientific Conference of the European Society of Coloproctology (ESCP) in Dublin, respectively. According to the World Health Organization; Cancer is one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Drs. Fan and Ward and other members of the UM Weil Institute recently published on the technology’s ability to diagnose COVID-19, including the ability to distinguish between variants of COVID-19. The group has also previously demonstrated the technology’s promise in diagnosing and monitoring ARDS, which is the most severe form of lung injury affecting more than 200,000 patients a year.

“We are extremely pleased to have the opportunity to work with the University of Michigan, one of the world’s leading research institutes. Together, we will reduce cancer mortality through early and accurate cancer detection and improve care for the seriously ill and injured. Blu Biotech’s expertise in the development of biomarkers, combined with University of Michigan patented hardware, data science and clinical expertise provide a realistic point-of-care commercial breathalyzer for the first time,” said Robert Tavzel, Chief executive officer. “At Blu Biotech, we continue to expand and develop respiratory biomarkers. One day soon, we will be able to target many other cancers, autoimmune diseases, infectious diseases and even potentially life-saving neurological and heart diseases through early detection.

Link to full article:

Contact: Robert Tavzel
[email protected]


View original content:

SOURCEBlu Biotech Inc.


About Author

Comments are closed.